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BioradiotherapyObjectives: To explore prognostic and predictive value of radiomics in patients with locally advanced
head and neck squamous cell carcinomas (LAHNSCC) treated with concurrent chemoradiotherapy
(CRT) or bioradiotherapy (BRT).
Materials and Methods: Data of 120 patients (CRT vs. BRT matched 2:1) were retrospectively analyzed. A
total of 544 radiomics features of the primary tumor were extracted from radiotherapy planning com-
puted tomography scans. Cox proportional hazards models were used to examine the association
between survival and radiomics features with false discovery rate correction. The discriminatory perfor-
mance was evaluated using receiver operating characteristic curve analysis.
Results: Multivariate analysis showed a 24-feature based signature significantly predicted for OS
(HR = 0.3, P = 0.02) and progression-free survival (PFS) (HR = 0.3, P = 0.01). Combining the radiomics sig-
nature with p16 status showed a significant improvement of prognostic performance compared with p16
(AUC = 0.78 vs. AUC = 0.64 at 5 years, P = 0.01) or radiomics signature (AUC = 0.78 vs. AUC = 0.67,
P = 0.01) alone. When patients were stratified according to this combination, OS and PFS were signifi-
cantly different according to the 4 sub-types (p16+ with low/high signature score; p16 with low/high
signature score) (P < 0.001). Patients with high signature score significantly benefited from CRT (vs. BRT)
in terms of OS (P = 0.004), while no benefit from CRT in patients with low signature score.
Conclusion: Our analysis suggests an added value of radiomics features as prognostic and predictive bio-
marker in HNSCC treated with CRT/BRT. Moreover, the radiomics signature provided additional informa-
tion to HPV/p16 status to further stratify patients. External validation of such findings is mandatory given
the risk of overfitting.
 2017 Elsevier Ltd. All rights reserved.Introduction chemoradiotherapy (CRT), although it is associated with frequentThe current standard of care for patients with locally advanced
head and neck squamous cell carcinoma (LAHNSCC) is concurrentsevere acute and late toxicities [1]. In the recent years there has been
a growing interest in increasing the benefit/risk ratio in human
papillomavirus (HPV)-positivepatients [2,3]. Due to improvedprog-
nosis, CRT could be safely postponed inHPVpositivepatients, reduc-
ing toxicitywhile not jeopardizing survival. Despite the overall good
prognosis for HPV+ population, a substantial proportion of these
patients remain at risk of recurrence and death [4]. Current recogni-
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classification, performance status and comorbidities. Additional
biomarkers are needed to further stratify patients and select candi-
dates for studies testing de-intensification approaches.
Generally, tissue or blood sampling is required to evaluate most
of the biomarkers. Invasive biopsies performed with that purpose
are prone to sampling bias and may not be able to accurately
reflect true heterogeneity of the entire tumor. Easily-obtainable,
noninvasive prognostic biomarkers that allow assessment of tumor
heterogeneity are lacking.
Inspired by the high-throughput success of the ‘‘omics”, there
has been resurgent interest in radiomics, which converts imaging
data into a high dimensional mineable feature space, by using a
large number of automatically extracted data-characterization
algorithms [5]. Radiomics can provide a more comprehensive view
of the entire tumor. Recent studies demonstrated that radiomics
features had significant associations with clinical factors and
underlying genomic patterns in various cancer types, thus showed
strong prognostic performance [6–9]. In head and neck cancers,
computed tomography (CT) imaging is routinely used for patient
management, including diagnosis, radiation treatment planning
and surveillance. Therefore, radiomics has significant clinical
potential without adding additional imaging studies.
The purpose of this investigation was to develop a radiomics
signature to estimate overall survival (OS) in patients with locally
advanced head and neck squamous cell carcinomas (LAHNSCC)
treated with concurrent chemoradiotherapy (CRT) or bioradiother-
apy (BRT) and assess its incremental value to Human Papillomavirus
(HPV) and clinical risk factors for individual OS estimation, and
also to explore its predictive value.Materials and methods
Patients
The retrospective cohort consisted of 120 patients with
pathologically-confirmed head and neck squamous cell carcinoma
(HNSCC), stage III–IVb according to American Joint Committee on
Cancer (AJCC)/ International Union for Cancer Control (UICC)
TNM classification 2010. Patients received total radiation dose of
70 Gy, 2 cycles of concurrent CDDP or 3 cycles of concurrent
cetuximab were selected from the former study cohort of 265
patients [10,11]. Patients were matched according to each T and
N stages, with a 2:1 ratio of CRT vs. BRT patients. Institutional
research ethics board approval was obtained.
All patients received either one of the following two treatments
between June 2006 and October 2012: definitive radiotherapy
(RT) concomitantly with cisplatin (100 mg/m2 every 3 weeks on
days 1, 22, and 43) or cetuximab (initial loading dose of 400 mg/
m2 one week prior to RT, followed by weekly injection at 250 mg/
m2 during RT). Patients received either three-dimensional confor-
mal radiotherapy (3D-CRT) or intensity-modulated radiotherapy
(IMRT). External beam definitive RT was delivered with a total dose
of 70 Gy to the gross tumor volume (GTV) in 35 fractions (range 30–
35 fractions) at 5 fractions per week, withmedian overall treatment
time of 49 days (range 39–70 days). A dose of 60 Gy and 50–54 Gy
were delivered to the intermediate- and low-risk clinical target vol-
ume (CTV). The CTVswere each expanded using 3–5 mmmargins to
generate their respective planning target volumes (PTV). Patient
assessments in follow-up were previously described [10].CT imaging, image segmentation and radiomics analysis
Planning CT of radiotherapy was performed according to stan-
dard clinical scanning protocols at Gustave Roussy with a SiemensSomatom Sensation Open 24-slice scanner (Siemens Medical Solu-
tions, Forchheim, Germany). The most common pixel spacing was
(0.98 mm, 0.98 mm, 3 mm) for CT.
The GTV of primary tumor (GTV-T) as region of interest was
manually contoured on all CT slices by a radiation oncologist with
expertise in identifying head and neck cancers. The segmentation
was performed by using the treatment planning system (TPS) of
ISOGRAY (DOSIsoft, Cachan, France).
The images and structures were exported from TPS in DICOM
(Digital Imaging and Communications in Medicine) format. All
image analysis was performed with the OncoradiomicsTM research
software using Matlab R2012b (Oncoradiomics.com) [6]. In total,
544 radiomics image features were defined and were divided in
four groups: (I) tumor intensity, (II) shape, (III) texture and (IV)
wavelet features. Detailed definitions of all features and the extrac-
tion methods were previously described [6].Pathology
Three lm thick sections were cut from the paraffin-embedded
pretreatment biopsy specimens. HPV status was determined by
p16 expression staining with immunohistochemistry (IHC). We
considered p16 as positive when nuclear staining was >75% of
cells. Cytoplasmic only staining was considered as negative. All
assessments were performed by the same experienced pathologist,
who was blinded to the clinical and follow-up data.Statistical and bioinformatic analysis
Survival rates were calculated with the Kaplan–Meier method.
Survival times were defined as the time from the beginning of
radiotherapy until either the time of first event or the date that
the patient was last known to be alive (censored). Events were
death from any cause for OS, death or tumor progression for
progression-free survival (PFS), death or locoregional recurrence
for loco-regional control (LRC), and death or distant metastasis
for distant metastasis-free survival (DMFS). Survival curves were
compared using the log-rank test.
Hierarchical clustering was applied to reveal the grouping pat-
terns of patients. The correlation between the radiomics feature
clusters and clinicopathologic variables were analyzed by chi-
square test. Both traditional prognostic factors and radiomics fea-
tures underwent univariate Cox proportional hazards model
(CPHM) analysis. To adjust for multiple comparisons, a false dis-
covery rate (FDR) correction was performed for radiomics fea-
tures, and the FDR-corrected p values were calculated using the
Benjamini and Hochberg method. The radiomics features selected
as candidate indicators under UVA were conducted with the prin-
cipal component analysis (PCA). Variables with a p value <0.1 on
UVA entered the multivariate Cox regression analysis (MVA). In
the Cox model, continuous variables (PS, T, N, Charlson index,
age and radiomics signature score) were dichotomized. To allow
appropriate dichotomization, the Youden index was utilized to
choose a suitable cutoff point for the radiomics signature score
with optimum sensitivity and specificity according to receiver
operating characteristic curve (ROC) for predicting 5-year overall
survival. The robustness of prognostic performance of the radio-
mic signature was assessed using 10-fold cross validation by
dichotomizing patients according to the survival or death status
at 5 years (censored subjects within 60 months were excluded).
Two-sided P values <0.05 were considered to indicate a signifi-
cant difference. The above analyses were performed using SPSS
version 18.0 (SPSS Inc., Chicago, IL, USA) and R software version
3.2.4.
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Patient characteristics
Patients’ clinical and pathological characteristics are summa-
rized in eTable 1 in Supplement. In total, HPV/p16 status of 101
patients had been determined by IHC. There were no significant
distribution differences between CRT and BRT group except for
the p16 status distribution.
Survival and relapse
The median follow-up time was of 49.3 months (range 3.7–
103.9 months). The 3-year actuarial OS, PFS and LRC for the entire
population were 72.5%, 61.2%, and 72.1%, respectively. The 5-year
actuarial OS, PFS and LRC were 61.2%, 52.6%, and 72.1%,
respectively.
Hierarchical clustering
The hierarchical clustering of 120 patients based on radiomics
feature values is shown in Fig. 1. Unsupervised clustering revealed
4 clusters of patients with similar radiomics expression patterns.
We compared the 4 clusters of patients with clinical parameters,
and found significant correlation with T classification
(P = 3.3 ⁄ 105), primary tumor location (P = 0.01) and a non-
significant correlation with smoking status (P = 0.09), whereas no
correlation was observed with p16 status (P = 0.19) and N classifi-
cation (P = 0.22).
Identification of potential prognostic radiomics features and definition
of signature
UVA evaluating the correlation of radiomics features and OS
was performed for each of the 544 radiomics features. A total ofFig. 1. Heatmap displaying Z-scores of the feature values for the 544 radiomics feature
values, and green to represent low feature values. The columns represent patients and
showed 4 clusters of patients with similar radiomics expression patterns. In the bottom24 features remained statistically significant after FDR correction
(P = 0.045), of which 3 were intensity features, 6 were shape fea-
tures, 1 was texture features and 15 were wavelet features
(eTable 2 in Supplement). PCA was used for the 24 features. Three
principal components accounted for 87.6% (58.3%, 23.0%, and 6.3%,
respectively) of the variance. A radiomics signature was developed
from the first principal component. The factor loadings are given in
eTable 3 in Supplement.Prognostic value of the radiomics signature
We classified the patients into high-score or low-score group
using the optimal cutoff point of radiomics signature scores. The
radiomics signature showed prognosis capacity for predicting 5-
year survival in the whole population with an AUC of 0.67 (95%
CI, 0.58–0.76) (eFig. 1 in Supplement). MVA adjusted for clinico-
pathological factors showed that both the radiomics signature
score and p16 significantly predicted for OS (signature score:
HR = 0.3, 95%CI, 0.1–0.9, P = 0.02; p16: HR = 0.3, 95%CI, 0.1–0.9,
P = 0.03) and PFS (signature score: HR = 0.3, 95%CI, 0.1–0.8,
P = 0.01; p16: HR = 0.4, 95%CI, 0.2–1.1, P = 0.08) (Table 1). Com-
pared with patients with high scores, patients with low scores
had significantly better OS and PFS (eFig. 2 in Supplement). Spear-
man correlation showed no significant correlation between the
radiomics signature score and p16 status (rho = 0.06, P = 0.54).
The spearman correlation coefficient between smoking status, T
classification, N classification and PS with radiomics signature
score were 0.23 (P = 0.01), 0.41 (P < 0.001), 0.02 (P = 0.81), 0.30
(P < 0.001), respectively.
The patients were then divided into 4 sub-types: p16+ and low
signature score (PL); p16+ and high signature score (PH); p16 and
low signature score (NL) and finally p16 and high signature score
(NH). The AUC point estimates for this signature that incorporates
radiomics score and p16 status was significantly superior to radio-
mics signature score or p16 alone throughout follow-up (Fig. 2a).s for the whole cohort (N = 120). The heat map uses red to represent high feature
the rows indicate the 544 radiomics features. Unsupervised hierarchical clustering
color bars each color represents a specific class of sub-set.
Table 1
Univariate and multivariate analyses of overall survival and progression-free survival (N = 120).
Variable OS PFS
UVA MVAa UVA MVAa
HR P HR 95%CI P HR P HR 95%CI P
T3-4 classification (T1-2) 1.34 0.37 0.9 0.4–2.2 0.84 1.0 0.90 0.7 0.3–1.6 0.45
N2-3 classification (N0-1) 1.8 0.08 1.3 0.6–2.8 0.46 2.2 0.01 1.7 0.8–3.3 0.16
Never smoker (Current/Former smoker) 0.3 0.03 0.6 0.1–2.5 0.46 0.2 0.01 0.4 0.3–1.6 0.28
BRT (CRT) 1.5 0.19 1.5 0.13
p16+ (p16) 0.2 0.01 0.3 0.1–0.9 0.03 0.3 0.02 0.4 0.2–1.1 0.08
PS = 0 (PS  1) 0.5 0.03 0.9 0.4–1.8 0.68 0.4 0.003 0.8 0.4–1.5 0.46
Oropharynx (Non-oropharynx) 1.0 0.89 0.9 0.77
IMRT (no-IMRT) 0.3 0.11 0.4 0.09 0.5 0.2–1.9 0.34
Charlson index  2 (0–1) 1.2 0.56 1.4 0.25
Age  65 years (<65) 1.5 0.25 1.4 0.27
Male (Female) 1.2 0.68 1.6 0.22
Radiomics signature score low (high) 0.4 0.004 0.3 0.1–0.9 0.02 0.4 0.001 0.3 0.1–0.8 0.01
OS: Overall survival; PFS: progression-free survival; UVA: univariate analysis;MVA: multivariate analysis; HR: hazard ratio; CI: confidence interval; CRT: chemoradiotherapy
with concurrent cisplatin; BRT: bioradiotherapy with concurrent cetuximab; IMRT: intensity-modulated radiotherapy; PS: performance status.
a N = 101.
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score + p16, OS and PFS curves were significantly different accord-
ing to the 4 sub-types (p < 0.001). OS and PFS of the PL and NL sub-
groups were both significantly higher than their high signature
score-counterparts (OS: P = 0.03, P = 0.003; PFS: P = 0.01,
P = 0.002, respectively) (Fig. 2b,c).
The prognostic performance of the clinical factors (smoking sta-
tus, T, N classification and PS) which were significant in UVA for OS
were also analyzed. eTable 4 in Supplement shows AUC estimates
of 5-year OS of these factors alone and in combination with the
radiomics signature. All the AUC estimates of the 4 factors
improved when combining together with the radiomics signature
compared to the factors alone. However, the combination with
these factors didn’t significantly improve AUC compared to the
radiomics signature alone. The combination of radiomics signature
and p16 status demonstrated the highest AUC estimate (0.78, 95%
CI 0.68-0.88) among all the factors and combinations. According to
the 10-fold cross validation, the accuracy of radiomic signature
prognostic model for 5-year OS was 0.67, and 0.74 of radiomic sig-
nature +p16 prognostic model (Supplementary eTable 4).Predictive value of the radiomics signature
The 5-year OS of the CRT and BRT groups were 62.1% and 57.5%,
respectively (P = 0.20). The 5-year PFS of the two groups were
54.4% and 47.2%, respectively (P = 0.13). No significant differences
of OS and PFS were observed between the two treatment groups
(eFig. 3 in Supplement). However, when patients were further
stratified by radiomics signure score, patients with high signature
score significantly benefited more from CRT (vs. BRT) in terms of
OS (P = 0.004) and PFS (P = 0.001), while no benefit difference
between CRT and BRT in patients with low signature score
(P = 0.99, P = 0.90, respectively) (Fig. 3).Discussion
The utilization of imaging features is evolving from qualitative
interpretation to more sophisticated quantitative analysis—ra-
diomics, to non-invasively capture tumor phenotypic differences.
CT imaging features of tumor heterogeneity have been associated
with OS in patients with head and neck cancers, esophageal cancer,
colorectal cancer, and non-small cell lung cancer (NSCLC) among
others [6,12–14].Biomarker discovery with HNSCC is relatively limited. Although
HPV status is deemed to be the strongest prognostic marker in
HNSCC patients [15], to date, the standard treatment for HNSCC
is not different between HPV positive and HPV negative tumors.
Studies show that there is a small subgroup of HPV+ oropharyngeal
cancer patients with poor prognosis and they need to be identified
with more specific and selective markers [16]. The search for addi-
tional methods is ongoing, mainly based on smoking history and
tumor-infiltrating lymphocytes [17,18]. Meanwhile, for patients
with HPV-negative HNSCC, few prognostic factors other than
TNM classification, surgical margins, and extracapsular infiltration
has been identified. Novel, non-invasive biomarkers with high
prognostic and predictive performance are needed for risk stratifi-
cation and treatment personalization. We identified a 24-feature
signature as an independent predictor for HNSCC patients’ OS
and PFS.
CT imaging feature quantification of tumor heterogeneity has
been associated with HPV status of HNSCC. In the two analyses
of Sakai et al. [19,20], statistically significant differences in some
texture features between HPV+ and HPV HNSCC have been found.
However, a single radiomics feature may not have enough predic-
tive power. Parmar et al. identified different Lung and H&N radio-
mics cancer-specific feature subgroups and quantified their clinical
significance by clustering, combining clinical, imaging and gene
expression data with external validation sets [21]. Similar to the
study of Aerts et al. [6], our clustering analysis revealed different
clusters of patients with similar radiomics expression patterns,
and found significant correlation of radiomics clusters with T clas-
sification, primary tumor location and a non-significant correlation
with smoking status, which included the information of most of
the traditional prognostic clinical factors. In addition, recently it
is also reported that a 4-feature based radiomics signature showed
strong correlation with survival and distant metastasis across dif-
ferent cohorts and different types of cancers (NSCLC and HNSCC).
The concordance index (CI) in the training cohorts and validation
cohorts were ranging from 0.55 to 0.69 [6,9,22]. The AUC of the
ROC curve of our radiomics signature predicting 5-year OS was
0.67 (95%CI, 0.58–0.76), which was similar to the previous
reported results.
To the authors’ knowledge, the current study is the first assess-
ing the combining prognostic value of radiomics signature and p16,
and also the first exploring the predictive value of radiomics in
patients with LAHNSCC treated with CRT or BRT. The combination
showed superior improved predictive accuracy of OS compared to
p16 alone. Further, we demonstrated that the radiomics signature
Fig. 2. (a) Time-dependent AUC estimates through follow-up when applying 3
prognostic biomarkers. The regions between the two dashed lines of the same color
provide a 95% confidence interval for the corresponding AUC. (b) Kaplan-Meier
curves of overall survival for patients stratified by radiomics signature score and
p16: PL vs. PH, P1 = 0.03; NL vs. NH, P2 = 0.003. (c) Progression-free survival: PL vs.
PH, P3 = 0.01; NL vs. NH, P4 = 0.002.
Fig. 3. Kaplan-Meier curves for patients stratified by radiomics signature score and
concurrent treatment regimen. (a) Overall survival: low signature score, CRT vs. low
signature score, BRT, P1 = 0.99; high signature score, CRT vs. high signature score,
BRT, P2 = 0.004; (b) Progression-free survival: low signature score, CRT vs. low
signature score, BRT, P3 = 0.90; high signature score, CRT vs. high signature score,
BRT, P4 = 0.001.
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patients. This characterization of sub-population in addition of
HPV status for LAHNSCC patients might guide future treatment
selection, which would lead to improvement of quality of life
and/or survival.
Although evidences are emerging comparing CRT versus BRT for
treating LAHNSCC, so far published results are controversial [23].
Characterization of the optimal selection of patients benefiting
from concurrent cisplatin or cetuximab has yet to be defined. In
the study of Ou et al. [11], the benefit of CRT (vs BRT) were similar
in p16+ and p16/unknown populations. Meanwhile, our results
showed superior survival results using CRT compared to BRT in
D. Ou et al. / Oral Oncology 71 (2017) 150–155 155the sub-population of patients with high radiomics signature score,
while in patients with low signature score, the two concurrent reg-
imens showed no difference on treatment outcomes. In the study
of Aerts et al. the intratumour heterogeneity radiomics features
have been correlated with cell cycling pathways [6]. Thus the
underlying mechanism of our results could be that the antiprolifer-
ative drug--CDDP was more efficient for the tumors with increased
proliferation. These initial results implied that radiomics may play
a role in treatment selection.
Our current study has several limitations, and should be consid-
ered as a preliminary study with need for independent external
validation. It is a retrospective study with a relatively small popu-
lation. The characteristics of the enrolled population were hetero-
geneous and the selection of treatment might be biased, so that the
performance of the heterogeneity of features can be underesti-
mated. Further, our dataset includes patients from 2006 to 2012.
During this time period, the standard of care for CT acquisition
has evolved, which could potentially affect our analysis. Addition-
ally, HPV status was determined using p16 expression staining
with IHC, which is only a surrogate in the oropharynx, whereas
in our study other tumor sites were also included. No combining
tests (In situ Hybridization or polymerase chain reaction) for HPV
validation was performed. Nowadays imaging examinations rou-
tinely performed in clinical practice for HNSCC include multiple
modalities, such as CT, MRI, PET/CT, etc. An integrated radiomics
analysis of different imaging modalities could potentially provide
more information. It is also reported recently that radiomics is able
to identify different gene expressions [6,24], and the correlation of
radiomics with other potential biomarkers such as PD-1/PD-L1 is
not evaluated in our current analysis. In fact a parallel study of
molecular biomarkers in the same population is under planning
to further investigate the correlation of radiomics and other valu-
able biomarkers. Future work would also involve studying the sig-
nature in independent validation sets from other institutions.Conclusion
In the present study, we investigated the correlation of radio-
mics signature with survival and its predictive potential in
LAHNSCC patients treated with concurrent chemoradiotherapy or
bioradiotherapy. The signature had an additional discrimination
capability when added to p16 status, improving the prognostic
accuracy and allowing further stratifying patients according to
their risk of relapse. While these results require external validation
(ongoing), they add to the growing body of evidence that radiomics
quantification non-invasively predicts patients’ outcome and may
in the future be used to guide treatment selection.Role of the funding source
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